Thoracic Malignancy


2020. Lung cancer screening (ESR/ERS)

In Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. To date, there are no nationally organised LCS programmes worldwide. The recommendation is to set up and conduct demonstration programmes focusing, among other points, on methodology, standardisation, tobacco cessation, education on healthy lifestyle, cost-effectiveness and a central registry.

2020. Technology appraisal guidance (NICE) 

NICE technology appraisals on chemotherapy for lung cancer

2019. Lung cancer: diagnosis and management (NICE)

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

2018. Lung Cancer Screening (NCCN)

The NCCN Guidelines (1) describe risk factors for lung cancer (2) recommend criteria for selecting individuals with high-risk factors for screening (3) provide recommendations for evaluation and follow-up of lung nodules found during screening (4) discuss the accuracy of chest LDCT screening  (5) discuss the benefits and risks of LDCT screening.

2017. Early and locally advanced non-small-cell lung cancer (ESMO)

Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013. Small Cell Lung Cancer (ESMO)

Clinical Practice Guidelines for diagnosis, treatment and follow-up

2013. EGFR‑TK mutation testing locally advanced or metastatic NSCLC (NICE)

Epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing is indicated in adults with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). Patients with EGFR‑TK mutation-positive tumours gain more benefit from treatment with EGFR‑TK inhibitors than from standard chemotherapy treatment whereas patients mutation-negative tumours gain more benefit from standard chemotherapy than from EGFR‑TK inhibitors.

Leave a Reply

Your email address will not be published. Required fields are marked *